The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy
The protections extend through at least 2035, with the potential for further extensions
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
The NDA filing is supported by results from the phase III evERA Breast Cancer study
Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Subscribe To Our Newsletter & Stay Updated
